PubMed Health⌕ Search

Biomedical subjects

C F Lanata

Publications and source records attributed to C F Lanata.

41 records · Page 3Linked to original sources
PubMed1988

Seroepidemiology of Cryptosporidium infection in two Latin American populations.

An enzyme-linked immunosorbent assay was used to examine randomly selected sera from 389 children and adults in Lima, Peru, and 84 children in Maracaibo and Caracas, Venezuela, for IgM or IgG antibody to Cryptosporidium. In Peru and Venezuela, 19.8% and 15.5% of the study populations, respectively, were positive for both specific IgG and IgM antibodies, a result consistent with active or recent infection and representing a larger percentage than normally reported from stool examinations of individuals seeking medical attention. Sixty-four percent of subjects from each country had detectable levels of specific IgG, indicating infection sometime in life. Detection of specific IgG increased in the two- to three-year-old age-group, a result suggesting that this is a common age for infection. Persistence of IgG and, less often, IgM antibody response over 12 mo occurred in some subjects, although the significance of this finding is uncertain. Our findings suggest that Cryptosporidium infections are endemic in the communities surveyed and that most residents have been infected.

Adolescent↗
PubMed1983

Vi serology in detection of chronic Salmonella typhi carriers in an endemic area.

A passive haemagglutination assay measuring antibody to highly purified Vi antigen, known to be sensitive and specific for the detection of chronic Salmonella typhi carriers in a non-endemic area, was assessed in an endemic area. A reciprocal serum Vi antibody titre of 160 was found to have a sensitivity of 75%, specificity of 92%, and a high predictive value in screening for chronic S typhi carriers in high-risk population group (eg, women over 40 years). This simple assay can screen for chronic S typhi carriers even in areas where typhoid fever is highly endemic.

Adolescent↗
PubMed1981

Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli.

In vitro and animal experiments indicated that lactobacilli might prevent Escherichia coli from colonizing the intestine and may produce substances counteracting enterotoxin. Lactinex, a commercial preparation of dried Lactobacillus acidophilus and L. bulgaricus, is marketed for uncomplicated diarrhea. Preliminary experiments in nonfasting volunteers indicated that lactobacilli in this preparation colonized the small intestine for up to 6 h. To evaluate the protective efficacy of Lactinex, a double-blind randomized study was carried out in which 48 volunteers (23 receiving Lactinex and 25 receiving placebos) were challenged with E. coli strains that produced heat-stable or heat-labile enterotoxins or both. No significant differences between the two groups were noted with respect to attack rate, incubation period, duration of diarrhea, volume and number of liquid stools, and coproculture yields. These data suggest that this lactobacillus preparations does not prevent or alter the course of enterotoxigenic E. coli diarrhea in adults. Lack of efficacy occurred despite efforts to maximize small bowel colonization, including administration of Lactinex in milk and in a 6-hour-interval regimen during 36 h before and 96 h after challenge.

Adolescent↗